Although speech disorders represent an early and common manifestation of Parkinson's disease (PD), little is known about their progression and relationship to dopaminergic replacement therapy. The aim of the current study was to examine longitudinal motor speech changes after the initiation of pharmacotherapy in PD. Fifteen newly-diagnosed, untreated PD patients and ten healthy controls of comparable age were investigated. PD patients were tested before the introduction of antiparkinsonian therapy and then twice within the following 6 years. Quantitative acoustic analyses of seven key speech dimensions of hypokinetic dysarthria were performed. At baseline, PD patients showed significantly altered speech including imprecise consonants, monopitch, inappropriate silences, decreased quality of voice, slow alternating motion rates, imprecise vowels and monoloudness. At follow-up assessment, preservation or slight improvement of speech performance was objectively observed in two-thirds of PD patients within the first 3-6 years of dopaminergic treatment, primarily associated with the improvement of stop consonant articulation. The extent of speech improvement correlated with L-dopa equivalent dose (r = 0.66, p = 0.008) as well as with reduction in principal motor manifestations based on the Unified Parkinson's Disease Rating Scale (r = -0.61, p = 0.02), particularly reflecting treatment-related changes in bradykinesia but not in rigidity, tremor, or axial motor manifestations. While speech disorders are frequently present in drug-naive PD patients, they tend to improve or remain relatively stable after the initiation of dopaminergic treatment and appear to be related to the dopaminergic responsiveness of bradykinesia.

Department of Circuit Theory Faculty of Electrical Engineering Czech Technical University Prague Technická 2 160 00 Prague 6 Czech Republic

Department of Neurology and Centre of Clinical Neuroscience 1st Faculty of Medicine Charles University Prague Kateřinská 30 120 00 Prague 2 Czech Republic

Institute of Anatomy 1st Faculty of Medicine Charles University U nemocnice 3 128 00 Prague 2 Czech Republic

Zobrazit více v PubMed

J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4 PubMed

Neurology. 2000 Jan 25;54(2):458-62 PubMed

Arch Neurol. 1969 Oct;21(4):343-54 PubMed

Laryngoscope. 2007 May;117(5):831-4 PubMed

J Commun Disord. 2009 Mar-Apr;42(2):124-35 PubMed

J Neural Transm (Vienna). 2013 Feb;120(2):319-29 PubMed

J Speech Hear Disord. 1978 Feb;43(1):47-57 PubMed

Neurology. 1998 Dec;51(6):1592-8 PubMed

Mov Disord. 2009 Apr 15;24(5):716-22 PubMed

PLoS One. 2012;7(2):e32132 PubMed

J Acoust Soc Am. 2013 Sep;134(3):2171-81 PubMed

J Voice. 2011 Jan;25(1):76-82 PubMed

J Voice. 2014 Nov;28(6):673-80 PubMed

J Speech Lang Hear Res. 2014 Aug;57(4):1330-43 PubMed

N Engl J Med. 2006 Aug 31;355(9):896-908 PubMed

Mov Disord. 1995 Sep;10(5):562-5 PubMed

J Commun Disord. 2000 Jan-Feb;33(1):59-88 PubMed

Rev Neurol (Paris). 2010 Oct;166(10):800-10 PubMed

Lancet Neurol. 2004 Sep;3(9):547-56 PubMed

Int J Lang Commun Disord. 2000 Jul-Sep;35(3):407-18 PubMed

Parkinsons Dis. 2013;2013:389195 PubMed

J Acoust Soc Am. 2011 Jan;129(1):350-67 PubMed

J Neural Transm (Vienna). 2010 Feb;117(2):197-205 PubMed

J Neural Transm (Vienna). 2015 Aug;122(8):1135-42 PubMed

Mov Disord. 2011 Oct;26(12):2212-9 PubMed

Neurology. 1987 Sep;37(9):1539-42 PubMed

Behav Neurol. 1999 Jan 1;11(3):131-7 PubMed

Parkinsonism Relat Disord. 1997 Apr;3(2):111-6 PubMed

Mov Disord. 2011 Dec;26(14):2504-8 PubMed

Phys Ther. 2008 Jun;88(6):733-46 PubMed

Mov Disord. 2008 Mar 15;23(4):574-80 PubMed

PLoS One. 2012;7(10):e46541 PubMed

Short-term effects of transcranial direct current stimulation on motor speech in Parkinson's disease: a pilot study

Levodopa may modulate specific speech impairment in Parkinson's disease: an fMRI study

Speech disorder and vocal tremor in postural instability/gait difficulty and tremor dominant subtypes of Parkinson's disease

Comparative analysis of speech impairment and upper limb motor dysfunction in Parkinson's disease

Speech disorders in Parkinson's disease: early diagnostics and effects of medication and brain stimulation

Hypernasality associated with basal ganglia dysfunction: evidence from Parkinson's disease and Huntington's disease